OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET

Company Participants

Julie Silber - PCG Advisory
Josh Riggs - President and CEO
Andrea James - CFO
Ekke Schutz - Chief Science Officer

Conference Call Participants

Joseph Conway - Needham
Vidyun Bais - BTIG

Operator

Thank you for standing by. My name is Kayla, and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Julie Silber from PCG Advisory. Please go ahead.

Julie Silber

Thank you, Kayla, and thank you to everyone for joining us for today's conference call to discuss OncoCyte's third quarter 2024 financial results and recent operating highlights. If you have not seen today's shareholder letter, please visit OncoCyte's Investor Relations page at investors.oncocyte.com to read it. Today's prepared remarks build upon the information that was already shared in this robust letter. On today's call is OncoCyte's President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James.

Before turning the call over to Josh, I'd like to go over our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical are forward-looking statements. These statements are made pursuant to, and within the meaning of the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.

We encourage you to review the company's SEC filings, including the company's most recent Form 10-Q, which identifies the risks and uncertainties that may cause future actual results or events to differ materially from those